Top Markets
#1 MowCat MowCat +48.92%
#2 Velvet Velvet +38.78%
#3 Quack AI Quack AI +21.60%
#4 Derive Derive +18.03%
#5 Bermuda Shorts Bermuda Shorts +15.19%
#6 Audiera Audiera +14.78%
#7 aPriori aPriori +12.52%
#8 SkyAI SkyAI +12.41%
#9 Biconomy Biconomy +12.29%
#10 Cross Cross +11.36%
Coin of the day
MowCat MowCat
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Classifica tra le azioni #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Prezzo delle azioni
$1.85
Ultima sincronizzazione: 2024-08-19
Capitalizzazione di mercato
$3.96M
Variazione (1 giorno)
2.78%
Variazione (1 anno)
0.00%
Paese
US
Scambia MyMD Pharmaceuticals, Inc. (MYMD)

Categoria

Healthcare
Ricavi di MyMD Pharmaceuticals, Inc. (MYMD)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di MyMD Pharmaceuticals, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per MyMD Pharmaceuticals, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE